PT003 MDI Cardiovascular Safety Study
This study has been completed.
Sponsor:
Pearl Therapeutics, Inc.
Information provided by:
Pearl Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01349803
First received: May 5, 2011
Last updated: December 6, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease |
Drug: PT005 MDI Drug: PT001 MDI Drug: PT003 MDI Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-blind, Parallel Group, 14-day, Multi-Center Study to Evaluate the Safety of PT003, PT005, PT001 and Foradil® Aerolizer® (12 µg, Open Label) as Evaluated by Holter Monitoring, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
Resource links provided by NLM:
Further study details as provided by Pearl Therapeutics, Inc.:
Primary Outcome Measures:
- Change in Mean Heart Rate Average Over 24 Hours Post-dose [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]The primary safety objective of this study is to compare the change in mean heart rate averaged over 24 hours post-dose, following twice daily dosing over 14 days with PT003 MDI, PT005 MDI, PT001 MDI or Foradil Aerolizer compared to baseline in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Secondary Outcome Measures:
- Characterization of additional cardiovascular safety parameters [ Time Frame: 24 hours ] [ Designated as safety issue: Yes ]The secondary objective of the study is to further characterize additional cardiovascular safety parameters of all treatment groups including the maximum 24-hour heart rate, mean night-time and day-time heart rate, ventricular ectopic events, ventricular couplets, ventricular runs, the number of supraventricular runs, and sustained ventricular tachycardia (VT), supraventricular ectopic events, and other clinically relevant arrhythmias (such as atrial fibrillation).
| Estimated Enrollment: | 220 |
| Study Start Date: | May 2011 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | November 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PT005 MDI
PT005 MDI
|
Drug: PT005 MDI
PT005 MDI administered as two puffs BID for 14 days
|
|
Experimental: PT001 MDI
PT001 MDI
|
Drug: PT001 MDI
PT001 MDI administered as two puffs BID for 14 days
|
|
Experimental: PT003 MDI
PT003 MDI
|
Drug: PT003 MDI
PT003 MDI administered as two puffs BID for 14 days
|
|
Active Comparator: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
|
Drug: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
Other Name: Foradil® Aerolizer®
|
Eligibility| Ages Eligible for Study: | 40 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Signed written informed consent
- 40 - 80 years of age
- Clinical history of COPD with airflow limitation that is not fully reversible
- Females of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods
- Current/former smokers with at least a 10 pack-year history of cigarette smoking
- A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70
- A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of predicted normal values
- Able to change COPD treatment as required by protocol
- Acceptable baseline (Visit 2) Holter monitor recording
Key Exclusion Criteria:
- Women who are pregnant or lactating
- Primary diagnosis of asthma
- Alpha-1 antitrypsin deficiency as the cause of COPD
- Active pulmonary diseases
- Prior lung volume reduction surgery
- Abnormal chest X-ray (or CT scan) not due to the presence of COPD
- Hospitalized due to poorly controlled COPD within 3 months of Screening
- Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy)
- Cancer that has not been in complete remission for at least 5 years
- Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives
- Clinically significant abnormal findings during the baseline Holter recording
- Patients with a pacemaker or ICD/CRT/CRT_D devices
Other inclusion/exclusion criteria as defined by the protocol
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01349803
Locations
| United States, Arizona | |
| Pearl Investigative Site | |
| Glendale, Arizona, United States | |
| United States, California | |
| Pearl Investigative Site | |
| Fullerton, California, United States | |
| Pearl Investigative Site | |
| Los Angeles, California, United States | |
| Pearl Investigative Site | |
| San Diego, California, United States | |
| United States, Florida | |
| Pearl Investigative Site | |
| Pensacola, Florida, United States | |
| United States, Louisiana | |
| Pearl Investigative Site | |
| Lafayette, Louisiana, United States | |
| United States, Massachusetts | |
| Pearl Investigative Site | |
| North Dartmouth, Massachusetts, United States | |
| United States, Michigan | |
| Pearl Investigative Site | |
| Livonia, Michigan, United States | |
| United States, Oregon | |
| Pearl Investigative Site | |
| Medford, Oregon, United States | |
| United States, Texas | |
| Pearl Investigative Site | |
| San Antonio, Texas, United States | |
| Australia, New South Wales | |
| Pearl Investigative Site | |
| Glebe, New South Wales, Australia | |
| Australia, Queensland | |
| Pearl Investigative Site | |
| Caboolture, Queensland, Australia | |
| Australia, South Australia | |
| Pearl Investigative Site | |
| Dawpark, South Australia, Australia | |
| Pearl Investigative Site | |
| Toorak Gardens, South Australia, Australia | |
| Australia, Victoria | |
| Pearl Investigative Site | |
| Heidelberg, Victoria, Australia | |
| Australia, Western Australia | |
| Pearl Investigative Site | |
| Nedlands, Western Australia, Australia | |
| New Zealand | |
| Pearl Investigative Site | |
| Caversham, Dunedin, New Zealand | |
| Pearl Investigative Site | |
| Private Bag, Hamilton, New Zealand | |
| Pearl Investigative Site | |
| Tauranga, North Island, New Zealand | |
| Pearl Investigative Site | |
| Newtown, Wellington, New Zealand | |
Sponsors and Collaborators
Pearl Therapeutics, Inc.
Investigators
| Study Director: | Colin Reisner, M.D. | Pearl Therapeutics |
More Information
No publications provided
| Responsible Party: | Colin Reisner, M.D./Chief Medical Officer, Pearl Therapeutics, Inc |
| ClinicalTrials.gov Identifier: | NCT01349803 History of Changes |
| Other Study ID Numbers: | PT003003 |
| Study First Received: | May 5, 2011 |
| Last Updated: | December 6, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Pearl Therapeutics, Inc.:
|
COPD |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Formoterol Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 22, 2013